Mass Spec Roundup: Peptides, Particles, Clocks, and Canines

From tandem MS peptide discovery to volatile saliva profiling, this week’s roundup follows hidden molecular patterns across cells, air, sediments, aging, and dogs

May 27, 2026
6 min

The Analytical Scientist

At a Glance

Category	Detail
Condition	Posttranslational Modifications Identification
Key Mechanisms	Transformer-based de novo peptide sequencing framework (RNovA) identifies peptides and unexpected modifications from tandem mass spectra.
Target Population	Biological samples including human cell digests and rheumatoid arthritis proteomics data.
Care Setting	Laboratory research and proteomics analysis.

Key Highlights

RNovA achieved state-of-the-art de novo sequencing performance on standard datasets.
Identified kynurenine-modified peptides validated with synthetic reference peptides.
Detected unannotated glutamic acid modification in a bacterial strain without a reference proteome.

Guideline-Based Recommendations

Diagnosis

Utilize RNovA for open posttranslational modification discovery.

Management

Apply RNovA for peptide sequence reconstruction from mass spectrometry data.

Monitoring & Follow-up

Benchmark RNovA against existing methods like PEAKS for performance evaluation.

Risks

Potential for missing modifications if relying solely on fixed candidate residue lists.

Patient & Prescribing Data

Human subjects in proteomics studies.

RNovA can enhance the identification of biologically relevant modifications in clinical samples.

Clinical Best Practices

Incorporate RNovA in proteomics workflows for comprehensive modification analysis.
Validate findings with synthetic reference peptides to ensure accuracy.